MSD
Pembrolizumab+ MK7684 (Vibostolimab)
Biodrugs/ Drugs
Cancer
A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematological Malignancies
2Phase II in Spain,
1Phase I